Chemotherapy dose intensity

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations

Chemotherapy treatment intensity (HDMTX exposure, intrathecal therapy doses, and cumulative dexamethasone dose) was not associated with any child self-reported or parent-reported behavioral symptoms o

Effect: null; RR 0.98 (95% CI 0.96-1.01) for HDMTX AUC on inattention; all p-values > 0.05 after FDR correction across all treatment-outcome combinations